Dasatinib: Clinical Trials

23 trials of Dasatinib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 completed, 4 active not recruiting, 3 recruiting, 2 terminated. 23 Phase 3, 6 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 323Completed 11, Active not recruiting 4, Recruiting 3, Terminated 2, Not yet recruiting 1, Unknown 1, Withdrawn 1
Phase 26Recruiting 2, Active not recruiting 1, Completed 1, Unknown 1, Withdrawn 1

Follow Dasatinib: new trials by email Literature Review of Dasatinib trials Research Report on Dasatinib

Trials (filtered) newest first · largest first

All 23 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs
ELVN-001, TKI - Chronic Myeloid Leukemia (CML), Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
Phase 3RecruitingEnliven Therapeutics4502026-12-312026-11-18
A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
HS-10382, Imatinib, Dasatinib - Chronic Myeloid Leukemia
Phase 3Not yet recruitingJiangsu Hansoh Pharmaceutical Co., Ltd.4082026-12-012026-10-21
Newly-diagnosed Pediatric T-cell ALL Protocol
Venetoclax, Dasatinib, homoharringtonine - Acute Lymphoblastic Leukemia, Childhood Leukemia, Acute Lymphoblastic
Phase 2 / Phase 3RecruitingInstitute of Hematology & Blood Diseases Hospital, China6102025-03-112025-08-26
Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects
Lifestyle Intervention, Dasatinib 100 MG, Quercetin 1000mg - Obesity, Healthy Lifestyle
Phase 2 / Phase 3RecruitingCedars-Sinai Medical Center1602023-10-172026-03-18
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Imatinib, Nilotinib, Bosutinib - Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
Phase 3Active not recruitingNovartis Pharmaceuticals4052021-10-062026-08-28
Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration and Biopsy - B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Phase 3Active not recruitingNational Cancer Institute (NCI)3482021-01-252026-11-12
Dasatinib Versus Nilotinib for Treatment Naïve Chronic Myeloid Leukemia
Dasatinib 100 MG [Sprycel], Nilotinib 150mg oral capsule [Tasigna] - Chronic Myeloid Leukemia - Chronic Phase
Phase 3TerminatedHamad Medical Corporation102017-08-032019-01-23
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
Prednisone, Vincristine, Daunorubicin - Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma
Phase 2 / Phase 3Active not recruitingSt. Jude Children's Research Hospital7902017-03-292026-06-17
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
Pegaspargase, Erwinia asparaginase, Cyclophosphamide - Acute Lymphoblastic Leukemia, Pediatric
Phase 3Active not recruitingDana-Farber Cancer Institute5602017-03-032026-07-16
Dasatinib Holiday for Improved Tolerability
dasatinib (SPRYCEL®) - Myeloid Leukemia, Chronic
Phase 3CompletedUniversity of Jena2912016-08-012023-05-10
Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL
Chidamide, Dasatinib - Leukemia, Leukemia, Acute
Phase 2 / Phase 3UnknownNanfang Hospital, Southern Medical University1202016-02-142022-07-01
Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response
imatinib, nilotinib, dasatinib - Leukemia, Chronic Myeloid
Phase 3CompletedAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia2292015-06-102024-08-13
Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™)
Dasatinib, Cytarabine, Daunorubicin - Acute Myeloid Leukemia (AML)
Phase 3CompletedUniversity of Ulm2042014-07-012024-02-23
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
Clofarabine, Cyclophosphamide, Cytarabine - B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like
Phase 3CompletedNational Cancer Institute (NCI)59492012-02-292026-06-02
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
Placebo, Dasatinib, Docetaxel - Prostatic Neoplasms
Phase 3CompletedBristol-Myers Squibb19302008-10-012016-10-17
Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia
Imatinib, Dasatinib - Myeloid Leukemia, Chronic, Chronic Phase
Phase 3CompletedNewcastle University8142008-08-012018-04-24
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Asparaginase, Cyclophosphamide, Cytarabine - Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Phase 2 / Phase 3CompletedNational Cancer Institute (NCI)632008-07-142020-04-13
Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine, Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib - Acute Lymphoblastic Leukemia
Phase 3CompletedSt. Jude Children's Research Hospital6002007-10-292022-08-23
A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Dasatinib, Imatinib - Myeloid Leukemia, Chronic
Phase 3CompletedBristol-Myers Squibb5472007-09-012017-02-15
A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy
Dasatinib, Imatinib - Leukemia
Phase 3TerminatedBristol-Myers Squibb32007-04-012009-11-20

Showing 20 of 23. Sign in to see all of them.

Conditions studied

Precursor Cell Lymphoblastic Leukemia-Lymphoma (8)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (7)  ·  Leukemia (5)  ·  Leukemia, Myeloid, Chronic-Phase (5)  ·  Bronchiolitis Obliterans Syndrome (2)  ·  Philadelphia Chromosome (2)  ·  Burkitt Lymphoma (1)  ·  Leukemia, B-Cell (1)  ·  Leukemia, Myeloid, Accelerated Phase (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Lymphoma (1)  ·  Obesity (1)  ·  Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1)  ·  Prostatic Neoplasms (1)

Sponsors

Bristol-Myers Squibb (6)  ·  National Cancer Institute (NCI) (3)  ·  St. Jude Children's Research Hospital (2)  ·  Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (1)  ·  Cedars-Sinai Medical Center (1)  ·  Dana-Farber Cancer Institute (1)  ·  Enliven Therapeutics (1)  ·  Hamad Medical Corporation (1)  ·  Institute of Hematology & Blood Diseases Hospital, China (1)  ·  Jiangsu Hansoh Pharmaceutical Co., Ltd. (1)  ·  Nanfang Hospital, Southern Medical University (1)  ·  Newcastle University (1)  ·  Novartis Pharmaceuticals (1)  ·  University of Jena (1)  ·  University of Ulm (1)

Countries

United States (14)  ·  Australia (8)  ·  Canada (7)  ·  Germany (7)  ·  Italy (7)  ·  Hungary (6)  ·  United Kingdom (6)  ·  Austria (5)  ·  China (5)  ·  Czechia (5)  ·  France (5)  ·  Netherlands (5)  ·  Poland (5)  ·  Russia (5)  ·  South Korea (5)

Top investigators

Andreas Hochhaus, Prof. (1)  ·  Domenico Russo, Professor (1)  ·  Hartmut Doehner, Prof. Dr. (1)  ·  Hiroto Inaba, MD, PhD (1)  ·  Jane Apperley, MD (1)  ·  Melissa Burns, MD (1)  ·  Michael J Burke (1)  ·  Mohamed A Yassin (1)  ·  Nicolas Musi, MD (1)  ·  Richard E Clark, MD (1)  ·  Sima Jeha, MD (1)  ·  Stephen G O'Brien, MD (1)  ·  William B Slayton (1)

Results publications

PMID 39121442, PMID 16960978, PMID 19369231, PMID 20131302, PMID 20525995, PMID 22160483, PMID 22645182, PMID 23380743, PMID 24211163, PMID 24311723, PMID 24357015, PMID 24569263, PMID 24722180, PMID 24970932, PMID 25087182, PMID 26118315, PMID 27192969, PMID 29020310, PMID 29518185, PMID 29720733, PMID 29812996, PMID 30120281, PMID 31188727, PMID 31612640, PMID 32496902, PMID 33242441, PMID 34170389, PMID 34933343, PMID 36524980, PMID 37890117, PMID 38820078, PMID 39316653, PMID 40905823, PMID 40908865, PMID 41397287, PMID 41469545, PMID 41490515, PMID 41671463, PMID 42154791, PMID 42339511

NIH funding

U10CA098543 (2), 2008 (1), 2023 (1), F32CA141762 (1), P50GM115279 (1), R01AG075684 (1), R01CA090246 (1), R01CA140729 (1), R37CA036401 (1), U10CA180820 (1), U10CA180886 (1)